Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A blood stabilizer and its application

A blood stabilizer and blood technology, applied in the field of blood stabilizers, can solve the problems of not being able to provide DNA/RNA denaturation, and achieve the effect of preventing nucleated cell rupture, avoiding concentration increase, and preventing degradation

Active Publication Date: 2017-03-29
GUANGDONG ASCENDAS GENOMICS TECH CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although Kryofix has been used successfully, it does not provide adequate protection against DNA / RNA denaturation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A blood stabilizer and its application
  • A blood stabilizer and its application
  • A blood stabilizer and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] An embodiment of the blood stabilizer described in the present invention, the blood stabilizer described in the present embodiment comprises the components of the following concentrations:

[0026]

[0027] Wherein, the concentrations of the potassium dichromate and lecithin are mass percent concentrations.

[0028] The preparation method of the blood stabilizer described in the present embodiment is: at first, calculate β-cyclodextrin (molecular weight is 1135), disodium cromoglycate ( Molecular weight is 248.3), triflusal (molecular weight is 248.2), EDTA tripotassium salt (molecular weight is 406.5), and according to the total mass of blood stabilizer and the mass percentage concentration of its components, potassium dichromate and lecithin are calculated Then, weigh each component in the blood stabilizer according to the calculation result; finally, add the weighed components into a volumetric flask, add water to dissolve, and constant volume.

Embodiment 2

[0030] An embodiment of the blood stabilizer described in the present invention, the blood stabilizer described in the present embodiment comprises the components of the following concentrations:

[0031]

[0032]

[0033] Wherein, the concentrations of the potassium dichromate and lecithin are mass percent concentrations.

[0034] The preparation method of the blood stabilizer described in this embodiment is the same as that in Example 1.

Embodiment 3

[0036] An embodiment of the blood stabilizer described in the present invention, the blood stabilizer described in the present embodiment comprises the components of the following concentrations:

[0037]

[0038] Wherein, the concentrations of the potassium dichromate and lecithin are mass percent concentrations.

[0039] The preparation method of the blood stabilizer described in this embodiment is the same as that in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a blood stabilizer and its application for stabilizing blood samples. The blood stabilizer of the present invention comprises components at the following concentrations: β-cyclodextrin 10-300 μmol / L, disodium cromoglycate 15-350 μmol / L, potassium dichromate 0.01-0.5%, triflusalox 5-150 μmol / L L, lecithin 0.05-1.5%, EDTA tripotassium salt 2.5-5.0 μmol / L; wherein, the concentration of the potassium dichromate and lecithin is the mass percentage concentration. The blood stabilizer of the present invention can stabilize blood cells, prevent nucleated cells from breaking and release DNA in the cells, and avoid the increase of blood extracellular DNA concentration; at the same time, the blood stabilizer of the present invention can also prevent DNA from degrading in vitro and blood coagulation.

Description

technical field [0001] The invention relates to a blood stabilizer and an application thereof, in particular to a blood stabilizer capable of protecting blood cell membranes and resisting DNA degradation and an application thereof. Background technique [0002] Stabilizing blood samples is extremely important for the transportation of blood samples and the operation of the clinical trial process. After adding common anti-blood and anti-coagulant reagents when collecting whole blood samples, the blood needs to be analyzed or processed within 6 hours (no more than 12 hours at most). [0003] Formaldehyde, as a fixative, is the mainstay of clinical and research tissue and biological sample preservation. The rationale for the use of formaldehyde as a fixative is its propensity to form cross-links between structurally organized proteins and protein moieties of lipoproteins and glycoproteins. Formaldehyde, as a fixative, has some disadvantages. First of all, the slow penetratio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N1/28
Inventor 邓杏飞
Owner GUANGDONG ASCENDAS GENOMICS TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products